登录并加购，请在购物车里查看协议价、货期和发货地。
选择规格
变更视图
关于此项目
经验公式（希尔记法）:
C20H18FNO4
化学文摘社编号:
分子量:
355.36
MDL number:
NACRES:
NA.21
UNSPSC Code:
12352200
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to yellow
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
SMILES string
Fc1c(ccc(c1)c3cc(ccc3)OC)NC(=O)C2=C(CCC2)C(=O)O
InChI
1S/C20H18FNO4/c1-26-14-5-2-4-12(10-14)13-8-9-18(17(21)11-13)22-19(23)15-6-3-7-16(15)20(24)25/h2,4-5,8-11H,3,6-7H2,1H3,(H,22,23)(H,24,25)
InChI key
XPRDUGXOWVXZLL-UHFFFAOYSA-N
Biochem/physiol Actions
Orally active, potent dihydroorotate dehydrogenase (DHODH) inhibitor in cultures and in vivo.
Vidofludimus (4SC-101) is an orally active, potent dihydroorotate dehydrogenase (DHODH) inhibitor (human DHODH IC50 = 134 nM; IC50 = 13 µM against PHA-stimulated lymphocytes proliferation) that inhibits PHA-induced IL-17 secretion from human PBMCs (IC50 = 6 µM) and exhibits therapeutic efficacy in murine models of colitis (50-100 mg/kg/d via intragastric administration; chronic dextran sodium sulfate-induced and acute TNBS-induced colitis) and a rat model of renal transplantation in vivo (20 mg/kg/d p.o.).
Vidofludimus (4SC-101) is an orally active, potent dihydroorotate dehydrogenase (DHODH) inhibitor (human DHODH IC50 = 134 nM; IC50 = 13 µM against PHA-stimulated lymphocytes proliferation) that inhibits PHA-induced IL-17 secretion from human PBMCs (IC50 = 6 µM) and exhibits therapeutic efficacy in murine models of colitis (50-100 mg/kg/d via intragastric administration; chronic dextran sodium sulfate-induced and acute TNBS-induced colitis) and a rat model of renal transplantation in vivo (20 mg/kg/d p.o.).
警示词
Warning
危险代码
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Acute 1
存储类别
11 - Combustible Solids
怎么回事？
WGK 3
闪点 (F)
Not applicable
闪点 (°C)
Not applicable